iBio - IBIO Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IBIO shares.
View IBIO analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 1-year price targets for iBio's shares. Their IBIO share price forecasts range from $1.50 to $1.50. On average, they predict the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 374.7% from the stock's current price.
View analysts price targets for IBIO or view top-rated stocks among Wall Street analysts.

iBio's stock was trading at $0.4786 on January 1st, 2022. Since then, IBIO shares have decreased by 34.0% and is now trading at $0.3160.
View the best growth stocks for 2022 here.

iBio saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 9,660,000 shares, a drop of 9.1% from the August 31st total of 10,630,000 shares. Based on an average trading volume of 2,090,000 shares, the days-to-cover ratio is currently 4.6 days. Currently, 4.5% of the shares of the company are sold short.
View iBio's Short Interest.

iBio, Inc. (NYSEAMERICAN:IBIO) announced its earnings results on Monday, November, 15th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The biotechnology company had revenue of $0.21 million for the quarter. iBio had a negative net margin of 1,177.85% and a negative trailing twelve-month return on equity of 45.72%.

Shares of iBio reverse split on the morning of Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

iBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.12%), Renaissance Technologies LLC (0.53%), State Street Corp (0.35%), Northern Trust Corp (0.17%), Goldman Sachs Group Inc. (0.13%) and Virtu Financial LLC (0.06%). Insiders that own company stock include Eastern Capital Ltd, James P Mullaney, Robert L Erwin and Robert Matthew Lutz.
View institutional ownership trends.

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IBIO stock can currently be purchased for approximately $0.32.

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $68.94 million and generates $2.37 million in revenue each year. The biotechnology company earns $-23,210,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (302) 355-0650, via email at ir@ibioinc.com, or via fax at 302-356-1173.